GlassScriptPhysician profile
Todd H Robinson
NPI 1093870354
$4,175.61
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $333 · 2021: $268 · 2022: $1,160 · 2023: $1,174 · 2024: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,819 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,819.45 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.54 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $457.27 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $364.92 | 2019-2024 | Veozah, Myrbetriq |
| Allergan, INC. | $324.49 | 2019-2020 | |
| Pfizer INC. | $324.38 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $227.16 | 2020-2024 | |
| Glaxosmithkline, LLC. | $193.84 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Sanofi-Aventis U.S. LLC | $156.98 | 2019-2023 | |
| Dexcom, INC. | $123.09 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $111.97 | 2022-2023 | Mounjaro, Jardiance |
| Janssen Pharmaceuticals, INC | $99.58 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $81.53 | 2022 | |
| Abbott Laboratories | $80.43 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.47 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $76.99 | 2022-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.42 | 2022 | |
| Cranial Technologies, INC | $41.63 | 2022-2023 | Doc Band |
| Lundbeck LLC | $34.35 | 2024 | Rexulti |
| Mylan Specialty L.P. | $33.86 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.39 | 2022-2023 | Jardiance |
| Dynavax Technologies Corporation | $29.74 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2023 | Trintellix |
| Ibsa Pharma INC. | $15.82 | 2024 | Licart, Tirosint |
| Supernus Pharmaceuticals, INC. | $15.11 | 2022 | |
| Esperion Therapeutics, INC. | $15.09 | 2022 | |
| Sanofi Pasteur INC. | $13.59 | 2019 | |
| Amarin Pharma, INC. | $13.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.